Researchers analyzed prognostic gene mutations by targeted next-generation sequencing to identify predisposing factors for predicting overall survival at one month before transplantation. They enrolled 120 patients with nonremission acute myeloid leukemia who underwent first allogeneic hematopoietic stem cell transplantation (allo-HSCT) between 2005 and 2018.
[Bone Marrow Transplantation]
1254621 SBQACR3H items 1 apa default asc 1
Najima, Y., Sadato, D., Harada, Y., Oboki, K., Hirama, C., Toya, T., Doki, N., Haraguchi, K., Yoshifuji, K., Akiyama, M., Inamoto, K., Igarashi, A., Kobayashi, T., Kakihana, K., Okuyama, Y., Sakamaki, H., Harada, H., & Ohashi, K. (2020). Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplantation, 1–13. https://doi.org/10.1038/s41409-020-01016-9 Cite
Investigators examined the CD34+c-Kit+Flt3+ myeloid progenitor population as potential mutation carrier in all langerhans cell histiocytosis disease manifestations.
1254621 PATB8AGC items 1 apa default asc 1
Xiao, Y., van Halteren, A. G., Lei, X., Borst, J., Steenwijk, E. C., de Wit, T., Grabowska, J., Voogd, R., Kemps, P. G., Picarsic, J., van den Bos, C., & Borst, J. (n.d.). Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis. Blood. https://doi.org/10.1182/blood.2020005209 Cite
The authors discuss the history, biologic effect, and clinical impact of fusion genes in the field of myeloid leukemias.
The authors analyzed 60 patients with diffuse large B cell lymphoma treated with FDA-approved CD19 chimeric antigen receptor (CAR) T cells and report the incidence, risk factors, and management of infections during the first year after treatment.
[Blood Cancer Journal]
6445212 FRPN9CDP items 1 apa default asc 1
Wudhikarn, K., Palomba, M. L., Pennisi, M., Garcia-Recio, M., Flynn, J. R., Devlin, S. M., Afuye, A., Silverberg, M. L., Maloy, M. A., Shah, G. L., Scordo, M., Dahi, P. B., Sauter, C. S., Batlevi, C. L., Santomasso, B. D., Mead, E., Seo, S. K., & Perales, M.-A. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 10(8), 1–11. https://doi.org/10.1038/s41408-020-00346-7 Cite
Research advocates were eager to learn who Health and Human Services Secretary Alex Azar would appoint to the board and to see its ideological makeup. On July 31st they got their first look as it gathered online for a one-time meeting run by the National Institutes of Health.
Twitter has suspended the account of MeTooSTEM founder BethAnn McLaughlin after allegations emerged that the former Vanderbilt University neuroscientist fabricated the Twitter account of an apparently nonexistent female Native American anthropologist at Arizona State University who had claimed to be an anonymous victim of sexual harassment by a Harvard professor.
Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.
[Acta Pharmacologica Sinica]
6445212 JLV5JA2S items 1 apa default asc 1
Yu, X., Zhu, M., Wang, J., Li, H., Hu, P., Qing, Y., Wang, X., Wang, H., Wang, Z., Xu, J., Guo, Q., & Hui, H. (2020). LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis. Acta Pharmacologica Sinica, 1–11. https://doi.org/10.1038/s41401-020-0466-7 Cite
M1 and M2 macrophage viability and activation were mainly found to be unaffected by few‐layer graphene and MoS2 at doses up to 50 µg mL−1.
Genmab A/S announced that the European Myeloma Network in collaboration with Janssen Research & Development, LLC reported positive results from the Phase III APOLLO study of the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone (Pd) versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide and a proteasome inhibitor.
Continue reading “Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase III APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma”
MorphoSys AG and Incyte announced that the FDA has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
Scientists describe a framework by which an understanding of the processes that promote clonal hematopoiesis in inherited bone marrow failure syndromes may inform clinical surveillance strategies.
Investigators demonstrated the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using mismatched donor stem cell source.
[Bone Marrow Transplantation]
1254621 CB3IFP68 items 1 apa default asc 1
Dalle, J.-H., Balduzzi, A., Bader, P., Pieczonka, A., Yaniv, I., Lankester, A., Bierings, M., Yesilipek, A., Sedlacek, P., Ifversen, M., Svec, P., Toporski, J., Gungor, T., Wachowiak, J., Glogova, E., Poetschger, U., & Peters, C. (2020). The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplantation, 1–10. https://doi.org/10.1038/s41409-020-01014-x Cite